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Summary
An experiment (Exp. 1) was 
conducted to determine the effect of 
Excede® at arrival or at revaccination 
on morbidity, mortality, and gain in 
both feedlot and pasture receiving 
systems. A second experiment (Exp. 
2) was conducted to determine the 
effect of feedlot and pasture receiving 
systems on animal health. In Exp. 1, no 
treatment differences were observed for 
initial or final BW, or ADG. In Exp. 1, 
initial BW, treatment, receiving system 
(pasture or feedlot); and buyer of cattle 
explained the cumulative incidence of 
bovine respiratory disease (BRD). The 
incidence of BRD in this study was 
4.7%, 11.0%, and 13.8% for arrival, 
control, and revaccination treatments 
respectively. The arrival medication 
effectively reduced BRD incidence. BRD 
was less (P= 0.02) for pasture receiving 
than feedlot receiving, averaging 7.4% 
and 11.0% respectively. In Exp. 2 BRD 
was less for pasture receiving than 
feedlot receiving with 23% and 53% 
treated for BRD respectively. 
Introduction
As a general trend, the percentage 
of feedlot cattle fed as “calf-feds” 
relative to yearlings has increased 
in recent years. The increased 
trend of calf feeding can be a 
health management challenge for 
many feedlots. Administration of 
appropriate antibiotics to control 
BRD in cattle that are at high risk of 
developing BRD may be an important 
management option for producers. 
Often feedlots observe their greatest 
health challenges 10 to 14 days after 
receiving. 
In addition, calves transitioning 
from a pasture based ranch system 
to a feedlot can experience multiple 
stressors that weaken immune 
function. Receiving calves with a 
system like their previous ranch 
environment should reduce calf 
receiving stress. Therefore, receiving 
calves with a pasture based system 
has the potential to be a less stressful 
system than feedlot pen receiving. 
The objective of Exp. 1 was to 
determine the effect of Excede® at 
arrival or at revaccination (16-27 days 
post arrival) on morbidity, mortality, 
and gain of calves in both feedlot 
and pasture receiving systems. The 
objective of Exp. 2 was to determine 
the effect of pasture vs. feedlot 
receiving on morbidity and growth 
performance of freshly weaned calves.
Procedure
Exp. 1 - Three treatments were 
evaluated within a pasture receiving 
system and feedlot receiving system: 
1) control (no medication; CON), 2) 
Excede® (Pfizer Animal Health, New 
York, NY) on arrival (ARR), or ) 
Excede at revaccination (median 18 
days post arrival; range 16-27 days; 
REVAC). A total of 2,264 freshly 
weaned steer calves received at the 
University of Nebraska Agricultural 
Research and Development Center 
(Mead, Neb.) between Oct. 1 and 
Oct. 22 were used in this experiment. 
Steers were procured from three 
buyers representing northern 
Nebraska, central Nebraska, and 
western Nebraska from a mixture 
of “ranch-direct” and “sale barn” 
sources. Steers were penned by 
treatment group to minimize 
environmental or “herd-immunity” 
effects. The trial had a total of 12 
replications for each treatment. 
Twenty-one feedlot pens housed 20 
head/pen (88 ft2/head; 420 head 
total) to supply seven replications 
per treatment in a feedlot receiving 
system. The treatment groups were 
assigned randomly to one of 21 
pens. Fifteen pastures housed 12 
head/ 14-acre pasture (1,844 head 
total) for five reps per treatment. 
The treatment groups were assigned 
randomly to one of 15 pastures. 
Steers housed in the feedlot received 
ad libitum intake of a typical feedlot 
receiving ration containing (DM 
basis) % dry rolled corn, % wet 
corn gluten feed, % alfalfa, and 1% 
mineral supplement containing 15 
mg/steer daily Deccox® (Alpharma 
Inc., Fort Lee, NJ) and 200 mg/ 
steer daily Rumensin® (Elanco, 
Greenfield, IN). Steers on one pasture 
replication received only limited hay 
supplementation and 16 oz Corid® 
(Merial, Atlanta, Ga.) per 100 gallons 
twice for coccidiosis prevention. 
Pasture location, adequate pasture 
forage, and management did not 
require this replication to receive 
concentrate supplementation. Steers 
on all other pastures were provided 
 lb/head steer daily of wet corn 
gluten feed plus mineral supplement 
containing 15 mg/steer Decox and 
200 mg/steer Rumensin daily and 
cool-season grass. In addition, cattle 
on these pastures received ad libitum 
hay supplementation. 
Steers were assigned to treatments 
based on processing order within 
buyer at arrival, with every third 
animal assigned to each treatment. 
Steers’ panel ID tags were notched 
to identify treatment assignment. 
Calves were processed at arrival 
by receiving three separate tags for 
individual identification including 
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an electronic ID, panel tag, and metal 
clip tag. Calves were weighed and 
vaccinated with Bovi-Shield Gold 
5®, and Somubac® (Pfizer Animal 
Health). Calves also received a 
weight dependant dose of Dectomax 
Injectable® (Pfizer Animal Health) 
anthelmintic. Any calves having 
horns were dehorned and cauterized. 
Bull calves (51 head) were identified 
for banding upon completion of 
the study. Calves were revaccinated 
at 18 days (range 16-27 days) post 
arrival. They received vaccinations 
of Bovi-Shield Gold 5, Somubac 
and Ultrachoice 7® (Pfizer Animal 
Health). Individual animal BWs were 
collected. All pasture calves also 
received a dose of pinkeye vaccine 
(Schering-Plough, Kenilworth, N.J. 
Calves were individually weighed off 
trial after 1 days (range 26-9 days).
All pens and pastures were 
evaluated by the same pen riders 
within day to provide equal 
pull evaluation across antibiotic 
treatments. A post treatment 
interval (PTI) was not in effect for 
the calves after receiving Excede as 
pen riders were blind as to which 
cattle had received Excede to prevent 
preferential pulling of untreated 
calves. Calves that were categorized 
as respiratory pulls by the cattle 
crew, based on individual animal 
observation each day, were pulled, 
symptoms assessed, and treated 
with Draxxin® (Pfizer Animal 
Health, New York, N.Y.). When a sick 
calf was treated, panel ID tag was 
notched to prevent receiving Excede 
at revaccination (REVAC treatment 
only). Animals were returned to home 
housing units as soon as possible after 
treatment. Any animals receiving 
Draxxin were subject to a seven-day 
PTI before any secondary medication 
was administered. 
Initial, revaccination, and final 
BW were recorded for each animal. 
Average daily gain and respiratory 
disease incidence data were recorded 
for each animal. In addition, 
morbidity outcomes and causes were 
recorded. Body weights, ADG, and 
mortality data using the individual 
animal as the observation were 
compared using the Proc MIXED 
procedure of SAS to analyze for 
treatment effects. The Proc GENMOD 
procedure of SAS was used to 
analyze respiratory disease morbidity 
outcomes. An animal was determined 
to be a confirmed respiratory disease 
observation for the trial if the animal 
was treated for respiratory disease 
by the animal health personnel or if 
the animal died and was confirmed a 
respiratory disease dead.
Exp. 2 – In the fall of 1997 1,172 
head of freshly weaned ranch direct 
and sale barn sourced calves were 
received at the University of Nebraska 
Research Feedlot. The calves were 
randomly assigned to either feedlot 
pens or the same pastures used for 
Exp 1. Calves were managed similar to 
Exp. 1 except none of the calves were 
treated with preventative medication.
Results
Exp. 1 - No significant differences 
(P>0.05) of initial BW (575 ± 10 lb), 
revaccination BW (615 ± 12 lb), final 
BW (6 ± 14 lb), or ADG (1.85 ± 
0.21 lb/day) were observed due to 
medication treatment. The number of 
respiratory disease caused mortalities 
did not differ (P> 0.05) among 
treatments, albeit low. The number of 
respiratory disease caused mortalities 
was 1, 1, and 2 for ARR, CON, and 
REVAC treatments respectively. The 
variables of the GENMOD model that 
explained the incidence of respiratory 
diseases were initial BW, preventative 
antibiotic treatment, receiving system 
and buyer of cattle. Interactions of 
these variables were not significant 
(P> 0.05). 
Initial BW, accounting for 
medication treatment; affected 
(P<0.01) animal respiratory 
disease outcome with lighter calves 
being more likely to be treated for 
respiratory disease. Excede treatment 
at arrival affected (P<0.01) animal 
respiratory disease outcome. The 
respiratory disease cumulative 
incidence for this trial was 4.7%, 
11.0%, and 1.8% for ARR, CON, and 
REVAC treatments, respectively. The 
ARR treatment reduced respiratory 
disease cumulative incidence of this 
trial (P<0.01) compared to CON. The 
REVAC treatment did not reduce 
respiratory disease cumulative 
incidence. 
The BW and ADG differences of 
pasture and feedlot received steers are 
presented in Table 1. Receiving steers 
in a pasture based system compared 
to a feedlot system significantly 
reduced (P= 0.02) cumulative BRD 
incidence from 11.0% to 7.4%.
No difference of BW change due to 
preventative medication treatment is 
presumably due to the short window 
of study length (26 – 9 days on trial). 
The ineffectiveness of the REVAC 
treatment relative to the ARR can be 
explained by animals experiencing 
respiratory disease challenge and 
individual animal treatment prior 
to revaccination on days 16 – 27 
(Figure 1). The shorter bars of the 
ARR treatment indicate decreased 
incidence of BRD relative to the 
CON treatment. The ARR treatment 
significantly (P<0.01) improved 
animal health status by reducing BRD 
incidence from initial processing to 
revaccination. The decrease in CON 
and REVAC BRD incidence after day 
15 is due to the natural incidence cycle 
of BRD and not revaccination which 
occurred on average at day 18. 
Exp. 2 pasture and feedlot daily 
gain from arrival weight to 28 or 
42 days post receiving was similar. 
The percentage of calves treated for 
BRD in the feedlot receiving system 
was significantly greater than for the 
pasture receiving system with 5% 
and 2% treated within feedlot and 
pasture receiving, respectively.
In conclusion, preventative 
medication administered at arrival 
effectively reduced the incidence 
of respiratory disease by reducing 
Table 1. Exp. 1 differences in BW of pasture 
and feedlot received calves. Revac BW 
= Revaccination BW.
Item Pasture Feedlot
Initial BW, lb 585 589
Revac BW, lb 621 65
Final BW, lb 627 661
Trial ADG, lb 1.26 2.6
(Continued on next page)
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BRD during the first 15 days of 
arrival. Administering preventative 
medication at revaccination 
(median day 18) in Exp. 1 was not 
a feasible option for BRD control 
due to animals experiencing BRD 
prior to preventative medication 
administration. The low incidence 
of BRD (11% of controls) in Exp. 1 
did not maximize the potential value 
of preventative medication that is 
possible with calves at higher risk 
of BRD. However, part of the low 
incidence of BRD was due to pasture 
receiving as feedlot received control 
steer actual incidence of BRD was 
21.4%. The calves from this study 
will be followed to slaughter for lung 
tissue damage analysis, feedlot ADG 
calculation, and economic analysis. 
The data will be published in a future 
Nebraska Beef Cattle Report. 
Pasture receiving effectively 
improved animal health status by 
Figure 1. Treatment Incidence Density.  CON = no preventative medication,  ARR = preventative at initial processing, and REVAC = preventative at  
revaccination.
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reducing BRD incidence over feedlot 
receiving. 
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